Payment overview · 2025
General Payments
$193.63
10 reported records · 5 companies
Healthcare provider profile · identity verified
Craig D Schmalzried, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ELIZABETHTON, TN · NPI 1831167741
Verified facts
What the public records show
CMS Open Payments records show Craig D Schmalzried, M.D. received $193.63 in general payments during 2025 across 10 reported records.
Novo Nordisk Inc accounted for 38.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $75.23 | 38.9% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$47.72 | 24.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $40.44 | 20.9% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.68 | 9.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.56 | 6.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $193.63 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $47.72 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $47.56 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.67 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $26.93 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 63 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
63 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 421 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 285 | 74 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 249 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 224 | 59 |
| Omeprazole | Omeprazole | 195 | 60 |
| Atorvastatin Calcium | Atorvastatin Calcium | 185 | 55 |
| Tramadol Hcl | Tramadol Hcl | 176 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 173 | 37 |
| Amlodipine Besylate | Amlodipine Besylate | 172 | 45 |
| Furosemide | Furosemide | 171 | 48 |
| Diazepam | Diazepam | 164 | 20 |
| Lisinopril | Lisinopril | 158 | 44 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 139 | 35 |
| Losartan Potassium | Losartan Potassium | 131 | 42 |
| Simvastatin | Simvastatin | 131 | 33 |
| Potassium Chloride | Potassium Chloride | 116 | 29 |
| Promethazine Hcl | Promethazine Hcl | 109 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 108 | 33 |
| Metformin Hcl Er | Metformin Hcl | 106 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 102 | 15 |
| Famotidine | Famotidine | 93 | 22 |
| Meloxicam | Meloxicam | 93 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 24 |
| Trazodone Hcl | Trazodone Hcl | 90 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 88 | 22 |
| Alprazolam | Alprazolam | 84 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 22 |
| Metformin Hcl | Metformin Hcl | 82 | 25 |
| Sertraline Hcl | Sertraline Hcl | 82 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 81 | 22 |
| Clonazepam | Clonazepam | 78 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 28 |
| Lorazepam | Lorazepam | 72 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 20 |
| Carvedilol | Carvedilol | 70 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 15 |
| Pregabalin | Pregabalin | 64 | 12 |
| Eliquis | Apixaban | 63 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 62 | 14 |
| Cefdinir | Cefdinir | 61 | 34 |
| Allopurinol | Allopurinol | 60 | 17 |
| Montelukast Sodium | Montelukast Sodium | 60 | 19 |
| Prednisone | Prednisone | 58 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | suppressed |
| Januvia | Sitagliptin Phosphate | 51 | suppressed |
| Celecoxib | Celecoxib | 49 | 16 |
| Atenolol | Atenolol | 47 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | suppressed |
| Trulicity | Dulaglutide | 45 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 13 |
| Ibuprofen | Ibuprofen | 43 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 13 |
| Jardiance | Empagliflozin | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | 11 |
| Fluconazole | Fluconazole | 38 | 18 |
| Levofloxacin | Levofloxacin | 38 | 25 |
| Buspirone Hcl | Buspirone Hcl | 37 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | 11 |
| Ozempic | Semaglutide | 34 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | 11 |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Methocarbamol | Methocarbamol | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 16 |
| Ramipril | Ramipril | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 15 |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 13 |
| Glimepiride | Glimepiride | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 14 |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | 11 |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 12 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $193.63 · 10 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, ELIQUIS, MINIMED 780G, Ozempic, Rybelsus, VOQUEZNA, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error